USFDAAug 5, 2026, 07:33 AM
BriaCell FDA Clears IND for Bria-PROS+ Prostate Cancer Study
AI Summary
BriaCell Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for Bria-PROS+, allowing the company to initiate a Phase 1/2a clinical study for its next-generation personalized immunotherapy in prostate cancer. Bria-PROS+ is designed to activate multiple components of the immune system and previously received a $2 million grant from the US National Cancer Institute. This clearance marks a significant step in developing new treatment options for advanced prostate cancer patients.
Key Highlights
- FDA cleared Investigational New Drug (IND) application for Bria-PROS+.
- Enables BriaCell to initiate Phase 1/2a clinical study for prostate cancer.
- Bria-PROS+ is a next-generation personalized immunotherapy for prostate cancer.
- Program previously awarded a $2 million grant from the US National Cancer Institute.
- Preclinical data showed Bria-PROS+ activated adaptive and innate immune responses.
- BriaCell's Bria-IMT™ program is in Phase 3 pivotal trial for metastatic breast cancer.
Price Impact
More from BCTX